ROCKVILLE, Md., Aug. 15 /PRNewswire-FirstCall/ -- Novavax, Inc. announced today the publication of research findings in the August 1, 2007 online issue of Journal of Virology demonstrating the potential of the company's proprietary virus-like particle (VLP) technology to create a vaccine to prevent HIV/AIDS. The paper describes the discovery by Novavax scientists and colleagues from the University of Alabama-Birmingham, Emory University and Duke University, with funding by the National Institutes of Health, that improved HIV-1 VLPs can be produced to create potential new AIDS vaccines.
In this paper, the authors describe a new way to maximize the incorporation of the HIV-1 envelope glycoprotein gp160 into VLPs. HIV-1 gp160 is the major surface protein of the virus and a principal immunogenic target against HIV.
This research represents a very important step forward in our VLP-based vaccine program and an exciting development in our collaboration with leaders in the field of HIV vaccines," said Dr. Gale Smith, Vice President of vaccine development at Novavax "We have produced VLPs which bind to CD4 and chemokine receptors. These VLP's have certain 'conserved' HIV-1 gene sequences which do not change; therefore these neutralizing antibodies may be very effective -- all important characteristics for development of a safe and effective HIV vaccine."read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment